Webinar: Measuring Changes in Cytokine Expression—Improving Results Using Advanced Analytical Tools
Accurate interpretation of cytokine expression patterns in children is critical in helping to facilitate more accurate clinical decisions. While interest in cytokine measurements supporting clinical research continues to grow, one challenge for researchers is that the circulating profile of cytokines in children is complex and can vary by age and sex.
Watch this on-demand webinar to learn how a comprehensive database of platform-specific reference values using a healthy pediatric population is helping to improve interpretation of cytokine expression patterns by providing an important baseline for comparing laboratory test results in clinical practice. Listen as webinar presenters discuss the advantages of multi-analyte biomarker analysis techniques and why these methods continue to grow in popularity.
The CALIPER (Canadian Laboratory Initiative on Pediatric Reference Intervals) program established a comprehensive database of pediatric reference intervals for more than 180 clinical biomarkers.
The classification and grouping of cytokine results based on age and/or sex specific reference intervals is helping to drive more accurate interpretation of cytokine expression patterns
Researchers are using the automated Ella™ platform to reduce manual assay steps, conserve sample volumes, and accelerate time to results.
Lusia Sepiashvili, Ph.D., DABCC, FCACB: Dr. Sepiashvili is a board-certified Clinical Biochemist in the Department of Pediatric Laboratory Medicine at The Hospital for Sick Children. She is involved in numerous collaborative research studies as an Assistant Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto.
Rajiv Pande, Ph.D.: Pande is Director of Commercial Immunoassays at Bio-Techne. He was a co-founder of the technology venture that developed and commercialized the automated Ella immunoassay platform. Rajiv has served in technical, commercial and leadership roles across multiple ventures over the last two decades, and has created, developed and commercialized multiple technologies and products.